55296-17-8

Usage

Uses

Used in Pharmaceutical Industry:
3-AMINO-4-PHENYLAMINO-BENZOIC ACID is used as a potent and selective human prostaglandin E2 receptor subtype 4 (hEP4-R) antagonist for the treatment of endometriosis. Endometriosis is a painful disorder in which tissue similar to the lining of the uterus grows outside the uterus, causing discomfort and other complications. By acting as an antagonist to the hEP4-R, 3-AMINO-4-PHENYLAMINO-BENZOIC ACID can help alleviate the symptoms and improve the quality of life for patients suffering from this condition.

InChI:InChI=1/C13H12N2O2/c14-11-8-9(13(16)17)6-7-12(11)15-10-4-2-1-3-5-10/h1-8,15H,14H2,(H,16,17)

Upstream product

• 62-53-3 aniline 
• 2365-85-7 3-amino-4-fluorobenzoic acid 
• 453-71-4 3-nitro-4-fluorobenzoic acid 
• 96-99-1 4-chloro-3-nitrobenzoate 
• 16927-49-4 2-nitrodiphenylamine-4-carboxylic acid 

Downstream Products

• 56886-52-3 2-(2-methyl-1-phenyl-1H-benzoimidazol-5-yl)-benzothiazole 
• 56886-60-3 2-(2-methyl-1-phenyl-1H-benzoimidazol-5-yl)-benzooxazole 
• 21720-24-1 2'-methyl-1'-phenyl-1H,1'H-[2,5']bi[benzoimidazolyl] 
• 1256966-55-8 5-(benzothiazol-2-yl)-1-phenyl-2-(phenylmethoxy)methylbenzimidazole 
• 1256966-56-9 5-(benzothiazol-2-yl)-2-hydroxymethyl-1-phenylbenzimidazole 
• 1256966-57-0 5-(benzothiazol-2-yl)-2-(N,N-dimethylammo)methyl-1-phenylbenzimidazole 
• 514206-06-5 3-amino-4-phenylaminobenzoic acid methyl ester 

Relevant academic research and scientific papers

Structural Modifications of Benzimidazoles via Multi-Step Synthesis and Their Impact on Sirtuin-Inhibitory Activity

Benzimidazole derivatives have been shown to possess sirtuin-inhibitory activity. In the continuous search for potent sirtuin inhibitors, systematic changes on the terminal benzene ring were performed on previously identified benzimidazole-based sirtuin i

Design and synthesis of conformationally restricted inhibitors of active thrombin activatable fibrinolysis inhibitor (TAFIa)

A series of 4,5,6,7-tetrahydro-1H-benzimidazole-5-carboxylic acid and 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-7-carboxylic acid derivatives designed as inhibitors of TAFIa has been prepared via a common hydrogenation-alkylation sequence starting from the appropriate benzimidazole and imidazopyridine system. We present a successful design strategy using a conformational restriction approach resulting in potent and selective inhibitors of TAFIa. The X-ray structure of compound 5 in complex with a H333Y/H335Q double mutant TAFI indicate that the conformational restriction is responsible for the observed potency increase.

AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS

A compound depicted by the formula below, or a pharmaceutically acceptable salt or solvate thereof. wherein, R1 represents (1) a C3-6 alkyl group,(2) a C1-6 alkyl group substituted with one or more substituent group(s) sel

Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor

1-Phenylbenzimidazoles are shown to be a new class of ATP-site inhibitors of the platelet-derived growth factor receptor (PDGFR). Structure- activity relationships (SARs) are narrow, with closely related heterocycles being inactive. A systematic study of